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Sjögren’s syndrome (SS) is an autoimmune disorder in which lymphocytes infiltrate the exocrine glands, result-
ing in the development of sicca symptoms. Lymphocytes may also invade various other organs and cause diverse
symptoms. Interstitial pneumonia has been observed frequently in SS patients. Typically, the pneumonia responds
well to systemic steroids, and fatal cases are rare. We experienced a case of lymphocytic pneumonia accompa-
nied by SS and treated with cyclophosphamide pulse therapy, and we present details of the case herein. (Korean
J Intern Med 2011;26:108-111)
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INTRODUCTION
Sjögren syndrome (SS) is an autoimmune disease that is
characterized by lymphocyte infiltration of exocrine
glands, resulting in dryness of the mouth and eyes. In
addition, other organs can be involved, including the
joints, lungs, gastrointestinal tract, and blood vessels, with
concomitant diverse symptoms [1]. Interstitial pneumonia
is frequently observed in patients with SS, who commonly
present with a dry cough. Although the number of report-
ed cases of SS and interstitial pneumonia is limited, it
appears to respond well to systemic steroids [2]. Carrinon
and Liebow first described lymphocytic interstitial pneu-
monia (LIP) [3]. This type of pneumonia is characterized
by diffuse infiltration of lymphocytes and plasma cells.
The cause of LIP is unclear. However, it has been associat-
ed with idiopathic or acquired human immunodeficiency
virus (HIV), Epstein-Barr virus infection, and autoim-
mune disorders [4]. LIP has also been associated with SS;
25% of LIP patients have been reported to have SS [5].
However, there is limited information on SS patients with
LIP [6,7]. Here we describe a case of LIP with primary SS
and treatment with cyclophosphamide pulse therapy.
CASE REPORT
A 29-year-old man visited a local clinic due to respirato-
ry distress on mild exercise, accompanied by dry eyes and
mouth. He was an office worker, and past medical and
family histories were unremarkable. The patient was diag-
nosed with primary SS, and his chest computed tomogra-
phy (CT) showed interstitial pneumonia in both lung
fields. Oral administration of prednisolone and hydroxy-
chloroquine with additional symptomatic therapy for sicca
symptoms of the eyes and mouth were provided, but the
patient’s symptoms did not improve. Therefore, azathio-
prine and methotrexate were added to the treatment, but
these medications were discontinued due to exacerbation
of the symptoms. The patient was then referred to our
hospital, and his vital signs were as follows: blood pres-
sure 120/70 mmHg; pulse rate 78/min; respiration rateKim JY, et al. Lymphocytic interstitial pneumonia in primary Sjögren’s syndrome   109
20/min, and body temperature 36.7 C. The patient was
conscious and oriented; he appeared chronically ill. There
were corneal erosions noted on eye examination, a
decrease in lacrimal secretions with the 5-mm Schirmer
test, and xerostomia. Chest auscultation revealed crackles
in both lung fields; the heart sounds were normal. The
abdomen and extremities were unremarkable, and lym-
phadenopathy was not observed. 
The results of laboratory studies showed a white blood
cell count of 11,900/mm
2 (neutrophil 86.5%), hemoglobin
of 10.4 g/dL, and platelet count of 720,000/mm
2. The ery-
throcyte sedimentation rate and the C-reactive protein
were elevated at 66 mm/hr and 124.2 mg/L, respectively.
The serum biochemistry, including SGOT/SGPT, ALP, γ -
GT, and LDH values, were 13/19 IU/L, 191 IU/L, 46 IU/L,
and 252 IU/L, respectively (all within normal ranges).
However, the total protein was elevated at 10.9 g/dL and
the albumin was decreased at 2.5 g/dL. These findings
indicated a reversal of the albumin to globulin ratio. In
addition, the blood urea nitrogen, creatinine, and other
electrolyte test results, as well as the urine analysis, were
all within normal limits. The rheumatoid factor was 26
IU/mL and the antinuclear antibody was 1:40 with posi-
tive speckles and anti-SSA antibodies. Immunoglobulins
G, A, and M were all elevated at 6,224 mg/dL, 848
mg/dL, and 404 mg/dL, respectively. Protein elec-
trophoresis of the serum did not show a monoclonal peak.
Anti-SSB, anti-centromere, and anti-Jo-1 antibodies were
all negative. The arterial blood gas had a pH of 7.469, pO2
of 73.4 mmHg, pCO2 of 35.5 mmHg, and an HCO3 of 25.2
mmol/L. The results of the pulmonary function and pul-
monary diffusing capacity tests were consistent with mod-
Figure 1. (A) Lung window setting of thin-section computed
tomography (CT) at the level of the aortic valve shows multiple,
variable-sized, thin-walled cystic lesions throughout both lungs.
Poorly-defined small nodules are seen mainly in both lower
lobes (arrowheads). Subcarinal lymph node enlargement is also
noted (arrow). (B) Thin-section CT taken 2 months after 1A
shows slightly increased numbers of cysts and centrilobular
nodules in both lungs. (C) Thin-section CT taken 6 months after
1B shows no significant interval change in the extent of cysts
and nodules in either lung. Note postbiopsy scarring in the
right lower lobe (arrow).
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erate restrictive disorder. On transthoracic echocardiogra-
phy, the systolic pressure of the pulmonary artery was
normal at 22 mmHg, and the other findings were also
within normal limits. A plain chest radiograph showed a
diffuse interstitial shadow in both lung fields, and cysts of
different sizes distributed superiorly with numerous areas
of air in the upper and middle lung zones. Moreover, cen-
trilobular nodules were observed in the lower lung zone,
and extensive lymphadenopathy was seen in both the
hilar and mediastinum regions (Fig. 1A). We diagnosed
the patient with interstitial pneumonia associated with
primary SS, and increased the prednisolone to 1 mg/kg/day
after excluding the presence of infection. 
After 2 months, the symptoms did not worsen, and we
gradually reduced the prednisolone to 0.5 mg/kg/day.
However, the interstitial pneumonia progressed on the
follow-up CT (Fig. 1B). LIP was diagnosed by lung biopsy
(Fig. 2A and 2B) performed by video-assisted thoracic
surgery (VATS) under general anesthesia. There was no
evidence of malignancy in the biopsy specimen. We added
cyclophosphamide pulse therapy (800 mg/mon, 500
mg/m
2), discontinued the azathioprine and methotrexate,
and continued the prednisolone and hydroxychloroquine.
A follow-up CT scan after 6 months showed no further
disease progression (Fig. 1C). The patient’s symptoms,
including dyspnea on exertion, improved markedly. There
was no change in pulmonary function, diffusion capacity,
or arterial blood gas analysis on follow-up. The patient
continues to be followed in the ambulatory care clinic.
DISCUSSION
In LIP, lymphocytes and plasma cells diffusely infiltrate
the lungs. The lymphocytes, which consist of polyclonal B
and T cells, are distinguished from malignant lymphoma
by the proliferation of monoclonal B cells. Some investiga-
tors believe that LIP might occur prior to malignant dis-
ease. Malignant lymphoma has reportedly developed from
LIP [8]. The cause of LIP is not known. However, it is
thought to be related to autoimmune phenomena because
it is associated with SS, pernicious anemia, autoimmune
hemolytic anemia, idiopathic biliary cirrhosis of the liver,
and chronic active hepatitis. In addition, it has been
reported with HIV and Epstein-Barr virus [4,9]. 
Single or combination steroid therapy has been used
with success; however, the effect of treatment on disease
duration and side effects are unknown. According to some
reports, 52% of patients with LIP improved with this
treatment, and 11% of them remained clinically and radi-
ographically unchanged. In general, approximately 37% of
these patients become fatal after a mean of 20 months fol-
lowing diagnosis [4,9]. 
When SS involves the respiratory system, interstitial
lung disease and tracheobronchial sicca are the most com-
mon abnormalities. In addition, pleuritis and pulmonary
vasculitis may occur [10,11]. 
Interstitial pneumonia is observed in about 25% of all
patients with SS. CT scans may have a variety of different
findings, but clinically significant findings are rare. Lung
biopsy is usually not necessary. A biopsy is indicated when
the symptoms associated with the interstitial pneumonitis
Figure 2. (A) Small lymphoid aggregate with germinal center and alveolar septal thickening are present (H&E, ×40). (B) There is a
mixture of small lymphocytes, plasma cells, and histiocytes, which expand and widen the alveolar septa (H&E, ×200).
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are severe or unresponsive to therapy; in these cases,
malignant lymphoma must be ruled out. 
It is well known that primary SS is associated with inter-
stitial pneumonia. However, a nonspecific interstitial
pneumonia is more common. The frequency of an orga-
nizing pneumonia, common pneumonias, and LIP are
similar in patients with primary SS [12]. The treatment for
the interstitial pneumonia associated with primary SS
generally includes steroids, cyclophosphamide, and aza-
thioprine. The standard therapy for LIP has not been
established. Other immune suppressants, based on the
success of steroid treatment, have been used empirically.
Although new medications have been tried for treatment
of SS, including etanercept, infliximab, and interferon-α,
their efficacy has not been proven [2]. Rituximab, a mono-
clonal antibody against cell surface marker CD20, may
offer an effective treatment option for all of the symptoms
associated with SS [13,14].
In our case, the associated interstitial pulmonary dis-
ease was treated with azathioprine, methotrexate, and
steroids; however, this regimen was unsuccessful. After
the diagnosis of LIP was confirmed by an open lung biop-
sy, cyclophosphamide pulse therapy was added and con-
tinued for 6 months; symptoms then improved. There
were no progressive findings on the pulmonary function
test or chest CT results. In the future, rituximab may be
considered for progressive disease. 
Conflict of interest
No potential conflict of interest relevant to this article
was reported.
REFERENCES
1.  Daniels TE, Fox PC. Salivary and oral components of Sjögren’s
syndrome. Rheum Dis Clin North Am 1992;18:571-589.
2. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syn-
drome: new clinical and therapeutic concepts. Ann Rheum Dis 
2005;64:347-354.  
3.  Liebow A, Carrington C. Lymphocytic interstitial pneumonia. Am
J Pathol 1966;48:36a.
4. Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid inter-
stitial pneumonia: a narrative review. Chest 2002;122:2150-
2164. 
5. Alkhayer M, McCann BG, Harrison BD. Lymphocytic interstitial
pneumonitis in association with Sjogren's syndrome. Br J Dis
Chest 1988;82:305-309. 
6. Dalvi V, Gonzalez EB, Lovett L. Lymphocytic interstitial pneu-
monitis (LIP) in Sjögren’s syndrome: a case report and a review
of the literature. Clin Rheumatol 2007;26:1339-1343. 
7.  Yum HK, Kim ES, Ok KS, Lee HK, Choi SJ. Lymphocytic intersti-
tial pneumonitis associated with Epstein-Barr virus in systemic
lupus erythematosus and Sjögren’s syndrome. Complete remis-
sion with corticosteriod and cyclophosphamide. Korean J Intern
Med 2002;17:198-203. 
8. Fishback N, Koss M. Update on lymphoid interstitial pneumoni-
tis. Curr Opin Pulm Med 1996;2:429-433. 
9. Strimlan CV, Rosenow EC 3rd, Weiland LH, Brown LR.
Lymphocytic interstitial pneumonitis: review of 13 cases. Ann
Intern Med 1978;88:616-621. 
10. Vitali C, Tavoni A, Viegi G, Begliomini E, Agnesi A, Bombardieri
S. Lung involvement in Sjögren’s syndrome: a comparison
between patients with primary and with secondary syndrome.
Ann Rheum Dis 1985;44:455-461. 
11.  Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM.
Respiratory manifestations in primary Sjögren’s syndrome: a
clinical, functional, and histologic study. Chest 1985;88:226-229.
12.  Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH.
Interstitial lung disease in primary Sjögren syndrome. Chest
2006;130:1489-1495. 
13.  Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rit-
uximab and changes in serum B cell biomarkers in patients with
systemic complications of primary Sjögren’s syndrome. Ann
Rheum Dis 2007;66:351-357.
14. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement
of Sjögren’s syndrome after two infusions of rituximab (anti-
CD20). Arthritis Rheum 2007;57:310-317. 